Neodyne Biosciences Announces its First Commercial Sales for Patented embrace™ Advanced Scar Therapy to Plastic Surgeons in the Las Vegas Market

MENLO PARK, Calif., Feb. 5, 2013 /PRNewswire/ -- Neodyne Biosciences, Inc., today announced positive reception and product sales for its first commercially available product,  patented embrace™  Advanced Scar Therapy.  Several Plastic Surgeons in Las Vegas purchased product for upcoming patient procedures and the patented embrace™ product was very well received. Patented embrace™ is a device for use in the management of closed hyper-proliferative (hypertrophic and keloid) scars and has been shown, in clinical studies, to offer a highly significant difference between patented embrace™ treated scars compared to the control (standard-of-care treated) incision sites (p = 0.007).

Recent results from Neodyne's REFINE Trial (Scar Prevention and the Clinical Effectiveness of a Novel Mechano-modulating Polymer) convinced the Plastic Surgeons in Las Vegas that this product will help them improve their scar results for their patients.  The REFINE study was a randomized control clinical trial designed to assess the efficacy and tolerability of the patented embrace™ device when used to treat closed incisions following a surgical procedure.   The interim analysis demonstrated the efficacy of the patented embrace™ therapy within one of the most challenging scar-prone surgical procedures, an abdominoplasty (tummy tuck). 

"I was impressed with the embrace™ clinical data and technology and felt this could benefit my patients by helping to minimize scar formation," said busy plastic surgeon Dr. Stephen Miller (Las Vegas, NV). "Patients frequently express concerns about scarring after a surgical procedure and embrace™ is the only product that I know of that reduces the mechanical forces and tension on the wound which will address these concerns.  I am happy to have the embrace™ therapy available for all of my patients."

"We are excited to commercially launch embrace™ scar therapy in the United States and believe that our patented   scar therapy can become the treatment-of-choice for those patients concerned with the risk of post-surgical scarring," said Bill Beasley, President and COO of Neodyne.   "We expect embrace™   to successfully compete within the scar treatment market alongside Merz Pharmaceuticals LLC, Molnlycke Health Care, Johnson & Johnson ("JNJ"), Smith + Nephew ("SNN"), and multiple others".

About embrace™ Advanced Scar Therapy

A new approach to scar management, patented embrace™ Advanced Scar Therapy delivers mechano-modulation therapy to the injury site and surrounding tissues.   The device includes a simple disposable applicator that transfers a predetermined level of strain to a single use adhesive silicone sheet, which is then adhered over the closed scar.   This unique mechanism of action provides a uniform compressive strain, or stress-shield around a closed scar, which can minimize collagen proliferation and formation of scar tissue.  The patented embrace™ device has been FDA Cleared, and is in the beginning phase for initial market release.  The Neodyne embrace™ technology is protected by numerous issued and pending patents.  

About Neodyne Biosciences, Inc.

Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance.  The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring.   Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation.  It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide.  Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment. 

SOURCE Neodyne Biosciences, Inc.